pharmaphorum December 22, 2025
Deal-hungry Ipsen is at it again, pledging just over $1 billion for rights to an antibody-drug conjugate (ADC) for cancer developed by China’s Simcere Zaiming, that is due to start clinical testing next year.
The drug – codenamed SIM0613 – targets LRRC15, a cell membrane protein that is said to be highly expressed on various tumour types as well as cancer-associated fibroblasts – structural cells that help solid tumours grow but are rarely found on normal, healthy cells.
The protein – which is associated with tumours that arise from mesenchymal tissue like glioblastoma, sarcomas, and melanoma – is thought to influence tumour growth, as well as play a role in resistance to anticancer therapies.
According to Ipsen, which has development,...
Today's Sponsors
Today's Sponsor